Perrigo Co. Plc (PRGO)

Perrigo's stock price has experienced significant volatility and a notable decline over the past six months. The 52-week high for PRGO stock was $30.93, and the 52-week low was $12.17. As of February 6, 2026, the closing price was $14.64. Key events impacting the stock price include disappointing Q3 2025 financial results, a revised full-year 2025 outlook, a strategic review of its infant formula business, multiple class action lawsuits, and analyst downgrades.

Perrigo's product demand exhibits seasonality in certain categories. The company has noted lower cough and cold and allergy seasonal demand in comparison to previous years. Additionally, Perrigo has navigated soft seasonal demand in allergy, sun care, and blister care categories. This indicates that sales of products related to respiratory health, allergies, and sun protection are influenced by seasonal changes.

Perrigo Company plc (PRGO) is a leading provider of over-the-counter (OTC) health and wellness solutions, operating within the Health Technology sector, specifically in Pharmaceuticals: Major industry. The company focuses on consumer self-care products that enable individuals to proactively manage or treat self-manageable conditions. Perrigo operates through two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. Perrigo's product portfolio includes upper respiratory products, nutrition products, digestive health products, pain and sleep-aids, oral care products, healthy lifestyle products, skin care products, women's health products, and vitamins, minerals, and supplements. The company sells its products under various brands and also provides contract manufacturing services.

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. While legally headquartered in Dublin, Ireland for tax purposes, its operational headquarters are in Grand Rapids, Michigan, U.S. Approximately 70% of Perrigo's net sales originate from the U.S. healthcare system. In North America, the company's product mix heavily features private-label consumer health goods sold to major retailers. Internationally, Perrigo primarily generates revenue through its national brands.

Perrigo's brand reputation over the past year has been significantly impacted by issues surrounding its infant formula business. A class action lawsuit alleges that the company made false and misleading statements regarding its infant formula business. The stock has been described as having "value trap vibes" due to declining sales, weak guidance, and analyst downgrades. Despite these challenges, Perrigo states its belief in sustainability in the OTC industry and emphasizes conducting business with integrity.

Perrigo Company plc's stock ownership is distributed among institutional investors, insiders, and public/individual investors. Approximately 67.75% of the company's stock is owned by Institutional Investors, 0.33% by Insiders, and 31.92% by Public Companies and Individual Investors. Major institutional owners and shareholders include Price T Rowe Associates Inc /md/, Vanguard Group Inc, and BlackRock, Inc.